Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: An observational analysis

Stefano De Santis, Cristina Borghesi, Serena Ricciardi, Daniele Giovannoni, Alberto Fulvi, Maria Rita Migliorino, Claudio Marcassa

Research output: Contribution to journalArticle


Introduction: Cancer-related pain has a severe negative impact on quality of life. Combination analgesic therapy with oxycodone and pregabalin is effective for treating neuropathic cancer pain. We investigated the efficacy and tolerability of a dose-escalation combination therapy with prolonged-release oxycodone/naloxone (OXN-PR) and pregabalin in patients with non-small-cell lung cancer and severe neuropathic pain. Methods: This was a 4-week, open-label, observational study. Patients were treated with OXN-PR and pregabalin. Average pain intensity ([API] measured on a 0–10 numerical rating scale) and neuropathic pain (Douleur Neuropathique 4) were assessed at study entry and at follow-up visits. The primary endpoint was response to treatment, defined as a reduction of API at T28 ≥30% from baseline. Secondary endpoints included other efficacy measures, as well as patient satisfaction and quality of life (Brief Pain Inventory Short Form), Hospital Anxiety and Depression Scale, and Symptom Distress Scale; bowel function was also assessed. Results: A total of 56 patients were enrolled. API at baseline was 8.0±0.9, and decreased after 4 weeks by 48% (4.2±1.9; P

Original languageEnglish
Pages (from-to)4043-4052
Number of pages10
JournalOncoTargets and Therapy
Publication statusPublished - Jul 4 2016



  • Breakthrough cancer pain
  • Neuropathic cancer pain
  • Non-small-cell lung cancer
  • Opioids
  • Oxycodone/naloxone
  • Pregabalin

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this